The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup

Gaffney, David K.; Suneja, Gita; Ryu, Sang Young; McCormick, Mary; Plante, Marie; Mileshkin, Linda; Small, William; Bacon, Monica; Stuart, Gavin; Kitchener, Henry C

doi:10.1016/j.ijrobp.2015.02.054

Cited by 14 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The GCIG developed the CCRN to help promote cervical cancer clinical trials in countries where the disease is endemic (Suneja et al, 2015, Gaffney et al, 2015). To date, there have been over 80 accruals to CCRN clinical trials.…”

Section: Initiatives In Conducting Trials In Lmicsmentioning

confidence: 99%

“…Through the inaugural international meeting, it became clear that education, especially in radiation oncology and brachytherapy, and quality assurance in cervical cancer treatment were critical aspects in many LMICs. Adherence to implementation science priorities is necessary to follow and incorporate appropriate guidelines such as chemotherapy administration and use of brachytherapy in advanced cervical cancer (Gaffney et al, 2015). …”

Section: Initiatives In Conducting Trials In Lmicsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical trials in low and middle-income countries — Successes and challenges

Grover

Jhingran

et al. 2017

Gynecologic Oncology Reports

Self Cite

View full text Add to dashboard Cite

Gynecologic malignancies affect women in low and middle-income countries (LMICs) at equal or higher rates compared to high income countries (HICs), yet practice guidelines based on clinical trials performed in HICs do not routinely account for resource disparities between these regions. There is a need and growing interest for executing clinical trials in LMICs. This has led to the creation of multinational cooperative groups and the initiation of several ongoing clinical trials in Mexico, China, and Korea. In this article we describe the challenges involved in initiating clinical trials in LMICs, review current efforts within surgical, medical, and radiation oncology, and introduce high priority topics for future research.

show abstract

Section: Initiatives In Conducting Trials In Lmicsmentioning

confidence: 99%

Section: Initiatives In Conducting Trials In Lmicsmentioning

confidence: 99%

Clinical trials in low and middle-income countries — Successes and challenges

Grover

Jhingran

et al. 2017

Gynecologic Oncology Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…2015;92:506-508 46. Reproduced with permission from Gaffney DK, Suneja G, Ryu SY, et al The Cervix Cancer Research Network: a global outreach effort on behalf of the Gynecologic Cancer InterGroup.…”

mentioning

confidence: 99%

Cervical cancer: A global health crisis

Small

Bacon²,

Bajaj

et al. 2017

Cancer

Self Cite

873

587

View full text Add to dashboard Cite

Cervical cancer is the fourth most common malignancy diagnosed in women worldwide. Nearly all cases of cervical cancer result from infection with the human papillomavirus, and the prevention of cervical cancer includes screening and vaccination. Primary treatment options for patients with cervical cancer may include surgery or a concurrent chemoradiotherapy regimen consisting of cisplatin-based chemotherapy with external beam radiotherapy and brachytherapy. Cervical cancer causes more than one quarter of a million deaths per year as a result of grossly deficient treatments in many developing countries. This warrants a concerted global effort to counter the shocking loss of life and suffering that largely goes unreported. This article provides a review of the biology, prevention, and treatment of cervical cancer, and discusses the global cervical cancer crisis and efforts to improve the prevention and treatment of the disease in underdeveloped countries. Cancer 2017;123:2404-12. © 2017 American Cancer Society.

show abstract

“…Registration of outcome is common and research with PROMs in cancer patients shows that its use enhances patient-clinician communication, patientsatisfaction and eventually quality of care [6][7][8][9][10][11][12][13][30][31][32][33][34][35]. Partly due to the lack of capacity or funding for traditional follow-up, long-term follow-up is generally not available for high-volume elective treatments such as cholecystectomy, inguinal hernia repair, rubber band ligation of hemorrhoids etc.…”

Section: Discussionmentioning

confidence: 99%

“…Funded by health care companies, it is well-organized, validated and reliable according to (inter-) national guidelines and databases [6][7][8][9][10][11][12][13]. However, for benign pathology, follow-up after treatment is often not available.…”

Section: Introductionmentioning

confidence: 99%